MediSpend Acquires Real Life Sciences

January 27, 2025

MediSpend, a Susquehanna Growth Equity‑backed life sciences technology company, has acquired Real Life Sciences (RLS), a provider of advanced anonymization and redaction solutions for clinical trial data. The deal expands MediSpend's Governance, Risk and Compliance (GRC) capabilities—adding RLS Protect SaaS and expert anonymization services to support pharma, biotech and CRO clients with regulatory disclosure and participant privacy.

Buyers
MediSpend
Targets
Real Life Sciences
Industry
Cloud & SaaS
Location
Pennsylvania, United States
Transaction Type
Buyout

Explore More

Related Acquisitions

Track M&A activity that matters to you

Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.